ImunonIMNN 26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates IMNN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Imunon ranks worse than 105820% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Imunon's EBITDA for the
three
months ended in Mar. 2026 was $-4.14 Mil. Imunon's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Imunon's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Imunon (NAS:IMNN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Imunon EBITDA Margin % Related Terms
Imunon EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Imunon's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMNN vs PMCB, CURX, LABT: EBITDA Margin % Comparison
For the Biotechnology subindustry, Imunon's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imunon EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Imunon's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Imunon's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imunon (IMNN) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imunon and its competitors. According to the industry distribution chart, Imunon ranks #999999 out of 945 companies in the Biotechnology industry.
Is Imunon's EBITDA Margin % too high?
Imunon's current EBITDA Margin % is 0.00%. Based on the distribution chart, Imunon ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Imunon has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Imunon's EBITDA Margin % compare to PMCB and CURX?
According to the Biotechnology industry distribution chart, Imunon ranks #999999 out of 945 companies for EBITDA Margin %. This places Imunon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imunon and its competitors. Imunon's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Imunon (IMNN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Imunon's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Imunon (IMNN), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
26GF Score
Get the complete analysis for IMNN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMNN has been successfully added to your 
